5-Star Stocks Poised to Pop: Becton Dickinson
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical-device maker Becton, Dickinson and Company (NYS: BDX) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at BD's business and see what CAPS investors are saying about the stock right now.
BD facts
Headquarters (founded) | Franklin Lakes, N.J. (1897) |
Market Cap | $15.1 billion |
Industry | Healthcare equipment |
Trailing-12-Month Revenue | $8.0 billion |
Management | Chairman/CEO Vincent Forlenza |
Return on Equity (average, past 3 years) | 23.3% |
Cash/Debt | $2.2 billion / $4.2 billion |
Dividend Yield | 2.4% |
Competitors | Abbott Labs |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 98% of the 1,155 members who have rated BD believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, BigFatBEAR, succinctly summed up the BD bull case for our community: "Nice margins, [return on equity], cash flow, low payout ratio, and aggressive dividend growth all point to a long-term health care winner."
If you want market-topping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, BD may not be your top choice.
If that's the case, we've compiled a special free report for investors called "The 3 Dow Stocks Dividend Investors Need," which uncovers a few other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow theTrackPoisedToCAPS account.
The article 5-Star Stocks Poised to Pop: Becton Dickinson originally appeared on Fool.com.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Becton, Dickinson and Covidien. The Fool owns shares of Abbott. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
